Wegovy Pill (Oral Semaglutide) FDA Approval & Launch: 2026 Update
The Wegovy Semaglutide Pill Is Here
The first daily pill version of the blockbuster weight loss drug Wegovy launched in the U.S. on Monday, January 6, 2026. This follows a historic FDA approval in late December 2025. The pill contains semaglutide, the same active ingredient in injectable Wegovy and Ozempic.
Wegovy Semaglutide Pill Dosing and Pricing (Jan 2026)
Novo Nordisk has set a surprisingly competitive "self-pay" price for patients without insurance coverage.
- Starting Dose (1.5 mg): Available now for $149 per month.
- Mid-Range Dose (4 mg): Priced at $149 through April 15, 2026, after which it will rise to $199.
- Maintenance Doses (9 mg & 25 mg): Expected to cost $299 per month.
How it Works
The Wegovy pill mimics the GLP-1 hormone to control blood sugar, slow digestion, and reduce appetite. Clinical trials (OASIS) showed that consistent use of the daily pill resulted in an average weight loss of approximately 17% over 68 weeks.
When was the Wegovy pill approved by the FDA?
The FDA officially approved the Wegovy pill for chronic weight management on December 22, 2025. It is the first once-daily oral GLP-1 medication approved specifically for weight reduction in adults
Is the Wegovy pill available now?
Yes, the Wegovy pill launched in the United States on January 6, 2026. It is broadly available at retail pharmacies and through select telehealth providers like Medvi and Sprout Health.
How much does the Wegovy pill cost?
For cash-paying patients, the 1.5 mg starter dose is priced at $149 per month. Maintenance doses (9 mg and 25 mg) are expected to increase to approximately $299 per month.